LAK31

LAK31 is an investigational **small-molecule histone deacetylase inhibitor** being studied preclinically for **urological malignancies**, including germ cell tumors, urothelial carcinoma, renal cell carcinoma, and prostate cancer. Available evidence indicates that it inhibits **HDAC1, HDAC2, HDAC3, and HDAC6** with high affinity and shows antiproliferative activity across multiple urological cancer cell lines, with reported preferential activity in tumor cells relative to non-malignant control cells. In the cited academic work from **Heinrich Heine University Düsseldorf**, LAK31 appeared more potent in vitro than structurally related comparators such as entinostat and vorinostat, supporting its characterization as an **epigenetic antineoplastic research compound** that remains in early preclinical development rather than clinical-stage testing.